Vera Therapeutics Inc Class A VERA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $31.75
- Day Range
- $30.82–32.90
- 52-Week Range
- $19.07–56.05
- Bid/Ask
- $30.00 / $32.53
- Shares Outstanding
- 71.78M
- Market Cap
- $2.28B
- Volume/Avg
- 913,088 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 339
- Website
- https://www.veratx.com
Valuation
|
Metric
|
VERA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VERA
|
|---|---|
Quick Ratio | 13.30 |
Current Ratio | 13.64 |
Interest Coverage | −50.96 |
Quick Ratio
VERA
Profitability
|
Metric
|
VERA
|
|---|---|
Return on Assets (Normalized) | −53.15% |
Return on Equity (Normalized) | −64.95% |
Return on Invested Capital (Normalized) | −59.57% |
Return on Assets
VERA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Lhqhtpdq | Pqkkhl | $112B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rsgstzzvs | Fhtfd | $64B | |||
| argenx SE ADR
ARGX
| Ywssgpvc | Gvjj | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gyqkbpwj | Dhggg | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Qxjkfmxp | Kldxrzz | $24B | |||
| BioNTech SE ADR
BNTX
| Xrlhfyqkc | Txk | $22B | |||
| Incyte Corp
INCY
| Rdpjlctq | Mwyh | $20B | |||
| Moderna Inc
MRNA
| Njmzvjpdb | Dksk | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Fmxbkzb | Whq | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Zwtytsnwg | Ztj | $13B |
United States